未找到相关数据
Phase II Trial of Presurgical Treatment with Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H plus Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) with Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients with HER2+Breast Cancer
被引：1
作者：
Callahan, R. D.
Patel, R.
Chan, D.
Allison, M. A.
DiCarlo, B.
Bosserman, L. D.
Kennedy, A.
Zehngebot, L. M.
Miller, J.
Giuliano, A. E.
Spivack, B.
Lin, L-s
Slamon, D. J.
Hurvitz, S. A.
机构：
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[3] Canc Care Associates, Redondo Beach, CA USA
[4] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[5] Cent Coast Med Oncol, Santa Maria, CA USA
[6] Wilshire Oncol Med Grp, Pomona, CA USA
[7] Hematol & Oncol Consultants, Orlando, FL USA
[8] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA
[9] John Wayne Canc Inst, Santa Monica, CA USA
[10] San Antonio Community Hosp, Breast Ctr, Upland, CA USA
来源：
关键词：
D O I：
10.1158/0008-5472.SABCS10-P1-11-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1-11-12
引用
收藏
页数：1
相关论文